ProQR Therapeutics NV
PRQR2.010USD
-0.200-9.05%
交易中 （美東）報價延遲15分鐘
216.50M總市值
虧損本益比TTM
關於 ProQR Therapeutics NV 公司
ProQR Therapeutics NV 是一家位於荷蘭的臨牀前生物製藥公司。該公司致力於發現和開發用於治療嚴重遺傳疾病的核糖核酸 (RNA) 療法。該公司設計的治療候選藥物專門針對和修復從突變基因轉錄而來的缺陷信使 RNA 或信使核糖核酸 (mRNA)，以恢復正常或野生型蛋白質的表達和功能。其候選產品包括 QR-010（一種用於治療囊性纖維化 (CF) 的 RNA 寡核苷酸）和 QR-110（一種用於治療萊伯氏先天性黑蒙 (LCA) 的寡核苷酸）。
ProQR Therapeutics NV簡介
公司代碼PRQR
公司名稱ProQR Therapeutics NV
上市日期Sep 18, 2014
CEOMr. Daniel Anton de Boer
員工數量166
證券類型Ordinary Share
年結日Sep 18
公司地址Zernikedreef 9
城市LEIDEN
上市交易所NASDAQ Capital Market Consolidated
國家Netherlands
郵編2333 CK
電話31881667000
網址https://www.proqr.com/
公司代碼PRQR
上市日期Sep 18, 2014
CEOMr. Daniel Anton de Boer
ProQR Therapeutics NV公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Begona Carreno, Ph.D.
Ms. Begona Carreno, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Eli Lilly and Company
16.04%
Van Herk Investments
13.60%
Adage Capital Management, L.P.
6.27%
Privium Fund Management BV
4.74%
Affinity Asset Advisors LLC
3.32%
其他
56.03%
持股股東
持股股東
佔比
Eli Lilly and Company
16.04%
Van Herk Investments
13.60%
Adage Capital Management, L.P.
6.27%
Privium Fund Management BV
4.74%
Affinity Asset Advisors LLC
3.32%
其他
56.03%
股東類型
持股股東
佔比
Hedge Fund
20.24%
Corporation
16.04%
Family Office
13.60%
Investment Advisor
10.85%
Investment Advisor/Hedge Fund
4.75%
Research Firm
3.24%
Individual Investor
2.00%
Bank and Trust
0.06%
其他
29.22%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
111
41.23M
39.14%
-4.84M
2025Q2
122
61.04M
57.95%
-6.05M
2025Q1
131
62.09M
59.01%
-3.97M
2024Q4
135
61.46M
58.04%
+24.32M
2024Q3
126
39.02M
42.64%
-5.37M
2024Q2
127
38.86M
42.67%
-6.74M
2024Q1
137
38.95M
43.54%
-15.29M
2023Q4
162
39.95M
44.78%
-23.51M
2023Q3
167
40.45M
49.96%
-14.58M
2023Q2
170
45.68M
56.49%
-13.40M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Eli Lilly and Company
16.90M
16.04%
+3.52M
+26.35%
Dec 31, 2024
Van Herk Investments
14.33M
13.6%
+2.13M
+17.44%
Sep 29, 2025
Adage Capital Management, L.P.
6.60M
6.27%
-1.50M
-18.52%
Jun 30, 2025
Privium Fund Management BV
5.00M
4.74%
+11.93K
+0.24%
Jun 30, 2025
Affinity Asset Advisors LLC
3.50M
3.32%
+215.00K
+6.55%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.06M
2.91%
+1.70M
+124.72%
Jun 30, 2025
Sio Capital Management, LLC
2.08M
1.97%
+20.55K
+1.00%
Jun 30, 2025
abrdn Inc.
1.85M
1.76%
--
--
Jun 30, 2025
Kynam Capital Management LP
1.65M
1.57%
-100.54K
-5.75%
Jun 30, 2025
Dafna Capital Management, LLC
1.57M
1.49%
--
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Avantis International Small Cap Equity ETF
0.01%
Avantis International Small Cap Value ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis International Small Cap Equity ETF
佔比0.01%
Avantis International Small Cap Value ETF
佔比0%
Invesco NASDAQ Future Gen 200 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
